nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanfacine—CYP2C19—Sorafenib—liver cancer	0.118	0.384	CbGbCtD
Guanfacine—CYP2C9—Sorafenib—liver cancer	0.0982	0.319	CbGbCtD
Guanfacine—CYP3A4—Sorafenib—liver cancer	0.0571	0.185	CbGbCtD
Guanfacine—CYP3A4—Doxorubicin—liver cancer	0.0346	0.112	CbGbCtD
Guanfacine—Abdominal pain lower—Sorafenib—liver cancer	0.0289	0.058	CcSEcCtD
Guanfacine—Testicular disorder—Epirubicin—liver cancer	0.0196	0.0393	CcSEcCtD
Guanfacine—Testicular disorder—Doxorubicin—liver cancer	0.0181	0.0364	CcSEcCtD
Guanfacine—Skin exfoliation—Sorafenib—liver cancer	0.00877	0.0176	CcSEcCtD
Guanfacine—Retrosternal pain—Epirubicin—liver cancer	0.00842	0.0169	CcSEcCtD
Guanfacine—Retrosternal pain—Doxorubicin—liver cancer	0.0078	0.0157	CcSEcCtD
Guanfacine—Cardiac failure congestive—Sorafenib—liver cancer	0.00735	0.0148	CcSEcCtD
Guanfacine—Renal failure acute—Sorafenib—liver cancer	0.00722	0.0145	CcSEcCtD
Guanfacine—Dermatitis exfoliative—Sorafenib—liver cancer	0.00706	0.0142	CcSEcCtD
Guanfacine—Pain in extremity—Sorafenib—liver cancer	0.00667	0.0134	CcSEcCtD
Guanfacine—Abdominal pain upper—Sorafenib—liver cancer	0.00609	0.0122	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Sorafenib—liver cancer	0.00588	0.0118	CcSEcCtD
Guanfacine—Dysphagia—Sorafenib—liver cancer	0.00576	0.0116	CcSEcCtD
Guanfacine—Abdominal discomfort—Sorafenib—liver cancer	0.00552	0.0111	CcSEcCtD
Guanfacine—Erectile dysfunction—Sorafenib—liver cancer	0.00531	0.0107	CcSEcCtD
Guanfacine—Acute coronary syndrome—Sorafenib—liver cancer	0.00506	0.0102	CcSEcCtD
Guanfacine—Myocardial infarction—Sorafenib—liver cancer	0.00503	0.0101	CcSEcCtD
Guanfacine—Hypokinesia—Epirubicin—liver cancer	0.00503	0.0101	CcSEcCtD
Guanfacine—Hypokinesia—Doxorubicin—liver cancer	0.00465	0.00935	CcSEcCtD
Guanfacine—Tinnitus—Sorafenib—liver cancer	0.0043	0.00864	CcSEcCtD
Guanfacine—Immune system disorder—Sorafenib—liver cancer	0.00416	0.00837	CcSEcCtD
Guanfacine—Alopecia—Sorafenib—liver cancer	0.00407	0.00819	CcSEcCtD
Guanfacine—Dysgeusia—Sorafenib—liver cancer	0.00393	0.0079	CcSEcCtD
Guanfacine—Muscle spasms—Sorafenib—liver cancer	0.00386	0.00776	CcSEcCtD
Guanfacine—Nocturia—Epirubicin—liver cancer	0.00366	0.00735	CcSEcCtD
Guanfacine—Syncope—Sorafenib—liver cancer	0.0036	0.00724	CcSEcCtD
Guanfacine—Loss of consciousness—Sorafenib—liver cancer	0.00353	0.00709	CcSEcCtD
Guanfacine—Atrioventricular block—Epirubicin—liver cancer	0.0035	0.00703	CcSEcCtD
Guanfacine—Hypertension—Sorafenib—liver cancer	0.00347	0.00697	CcSEcCtD
Guanfacine—Myalgia—Sorafenib—liver cancer	0.00342	0.00687	CcSEcCtD
Guanfacine—Arthralgia—Sorafenib—liver cancer	0.00342	0.00687	CcSEcCtD
Guanfacine—Nocturia—Doxorubicin—liver cancer	0.00338	0.0068	CcSEcCtD
Guanfacine—Dry mouth—Sorafenib—liver cancer	0.00334	0.00672	CcSEcCtD
Guanfacine—Skin exfoliation—Epirubicin—liver cancer	0.00324	0.00651	CcSEcCtD
Guanfacine—Atrioventricular block—Doxorubicin—liver cancer	0.00324	0.00651	CcSEcCtD
Guanfacine—Shock—Sorafenib—liver cancer	0.00322	0.00648	CcSEcCtD
Guanfacine—Diclofenac—CYP2E1—liver cancer	0.00318	0.394	CrCbGaD
Guanfacine—Diclofenac—CYP1A1—liver cancer	0.00314	0.389	CrCbGaD
Guanfacine—Cramps of lower extremities—Epirubicin—liver cancer	0.00312	0.00627	CcSEcCtD
Guanfacine—Skin exfoliation—Doxorubicin—liver cancer	0.003	0.00603	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00298	0.006	CcSEcCtD
Guanfacine—Dyspnoea—Sorafenib—liver cancer	0.00292	0.00587	CcSEcCtD
Guanfacine—Cramps of lower extremities—Doxorubicin—liver cancer	0.00288	0.0058	CcSEcCtD
Guanfacine—Dyspepsia—Sorafenib—liver cancer	0.00288	0.0058	CcSEcCtD
Guanfacine—Decreased appetite—Sorafenib—liver cancer	0.00285	0.00572	CcSEcCtD
Guanfacine—Fatigue—Sorafenib—liver cancer	0.00282	0.00568	CcSEcCtD
Guanfacine—Constipation—Sorafenib—liver cancer	0.0028	0.00563	CcSEcCtD
Guanfacine—Vascular purpura—Epirubicin—liver cancer	0.00275	0.00554	CcSEcCtD
Guanfacine—Cardiac failure congestive—Epirubicin—liver cancer	0.00272	0.00546	CcSEcCtD
Guanfacine—Gastrointestinal pain—Sorafenib—liver cancer	0.00268	0.00538	CcSEcCtD
Guanfacine—Renal failure acute—Epirubicin—liver cancer	0.00267	0.00536	CcSEcCtD
Guanfacine—Dermatitis exfoliative—Epirubicin—liver cancer	0.00261	0.00525	CcSEcCtD
Guanfacine—Abdominal pain—Sorafenib—liver cancer	0.00259	0.00521	CcSEcCtD
Guanfacine—Purpura—Epirubicin—liver cancer	0.00256	0.00514	CcSEcCtD
Guanfacine—Vascular purpura—Doxorubicin—liver cancer	0.00255	0.00512	CcSEcCtD
Guanfacine—Cerebrovascular accident—Epirubicin—liver cancer	0.00251	0.00505	CcSEcCtD
Guanfacine—Lethargy—Epirubicin—liver cancer	0.00251	0.00505	CcSEcCtD
Guanfacine—Cardiac failure congestive—Doxorubicin—liver cancer	0.00251	0.00505	CcSEcCtD
Guanfacine—Renal failure acute—Doxorubicin—liver cancer	0.00247	0.00496	CcSEcCtD
Guanfacine—Pain in extremity—Epirubicin—liver cancer	0.00246	0.00495	CcSEcCtD
Guanfacine—Affect lability—Epirubicin—liver cancer	0.00242	0.00487	CcSEcCtD
Guanfacine—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00242	0.00486	CcSEcCtD
Guanfacine—Hypersensitivity—Sorafenib—liver cancer	0.00241	0.00485	CcSEcCtD
Guanfacine—Purpura—Doxorubicin—liver cancer	0.00236	0.00475	CcSEcCtD
Guanfacine—Asthenia—Sorafenib—liver cancer	0.00235	0.00472	CcSEcCtD
Guanfacine—Cerebrovascular accident—Doxorubicin—liver cancer	0.00233	0.00468	CcSEcCtD
Guanfacine—Lethargy—Doxorubicin—liver cancer	0.00233	0.00468	CcSEcCtD
Guanfacine—Pruritus—Sorafenib—liver cancer	0.00232	0.00466	CcSEcCtD
Guanfacine—Pain in extremity—Doxorubicin—liver cancer	0.00228	0.00458	CcSEcCtD
Guanfacine—Liver function test abnormal—Epirubicin—liver cancer	0.00227	0.00457	CcSEcCtD
Guanfacine—Orthostatic hypotension—Epirubicin—liver cancer	0.00225	0.00452	CcSEcCtD
Guanfacine—Abdominal pain upper—Epirubicin—liver cancer	0.00225	0.00452	CcSEcCtD
Guanfacine—Affect lability—Doxorubicin—liver cancer	0.00224	0.00451	CcSEcCtD
Guanfacine—Diarrhoea—Sorafenib—liver cancer	0.00224	0.00451	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00217	0.00437	CcSEcCtD
Guanfacine—Dizziness—Sorafenib—liver cancer	0.00217	0.00435	CcSEcCtD
Guanfacine—Asthma—Epirubicin—liver cancer	0.00213	0.00428	CcSEcCtD
Guanfacine—Dysphagia—Epirubicin—liver cancer	0.00213	0.00428	CcSEcCtD
Guanfacine—Liver function test abnormal—Doxorubicin—liver cancer	0.0021	0.00423	CcSEcCtD
Guanfacine—Vomiting—Sorafenib—liver cancer	0.00208	0.00419	CcSEcCtD
Guanfacine—Orthostatic hypotension—Doxorubicin—liver cancer	0.00208	0.00418	CcSEcCtD
Guanfacine—Abdominal pain upper—Doxorubicin—liver cancer	0.00208	0.00418	CcSEcCtD
Guanfacine—Rash—Sorafenib—liver cancer	0.00207	0.00415	CcSEcCtD
Guanfacine—Dermatitis—Sorafenib—liver cancer	0.00206	0.00415	CcSEcCtD
Guanfacine—Headache—Sorafenib—liver cancer	0.00205	0.00413	CcSEcCtD
Guanfacine—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.00201	0.00404	CcSEcCtD
Guanfacine—Asthma—Doxorubicin—liver cancer	0.00197	0.00396	CcSEcCtD
Guanfacine—Dysphagia—Doxorubicin—liver cancer	0.00197	0.00396	CcSEcCtD
Guanfacine—Pollakiuria—Epirubicin—liver cancer	0.00197	0.00395	CcSEcCtD
Guanfacine—Nausea—Sorafenib—liver cancer	0.00195	0.00391	CcSEcCtD
Guanfacine—Weight increased—Epirubicin—liver cancer	0.00194	0.00389	CcSEcCtD
Guanfacine—Drowsiness—Epirubicin—liver cancer	0.0019	0.00382	CcSEcCtD
Guanfacine—Conjunctivitis—Epirubicin—liver cancer	0.00185	0.00371	CcSEcCtD
Guanfacine—Sweating—Epirubicin—liver cancer	0.00182	0.00366	CcSEcCtD
Guanfacine—Pollakiuria—Doxorubicin—liver cancer	0.00182	0.00366	CcSEcCtD
Guanfacine—Weight increased—Doxorubicin—liver cancer	0.00179	0.0036	CcSEcCtD
Guanfacine—Drowsiness—Doxorubicin—liver cancer	0.00176	0.00353	CcSEcCtD
Guanfacine—Diclofenac—ALB—liver cancer	0.00175	0.217	CrCbGaD
Guanfacine—Bradycardia—Epirubicin—liver cancer	0.00173	0.00349	CcSEcCtD
Guanfacine—Rhinitis—Epirubicin—liver cancer	0.00171	0.00343	CcSEcCtD
Guanfacine—Conjunctivitis—Doxorubicin—liver cancer	0.00171	0.00343	CcSEcCtD
Guanfacine—Sweating—Doxorubicin—liver cancer	0.00168	0.00338	CcSEcCtD
Guanfacine—Visual impairment—Epirubicin—liver cancer	0.00164	0.0033	CcSEcCtD
Guanfacine—Bradycardia—Doxorubicin—liver cancer	0.00161	0.00323	CcSEcCtD
Guanfacine—Eye disorder—Epirubicin—liver cancer	0.00159	0.0032	CcSEcCtD
Guanfacine—Tinnitus—Epirubicin—liver cancer	0.00159	0.00319	CcSEcCtD
Guanfacine—Rhinitis—Doxorubicin—liver cancer	0.00158	0.00318	CcSEcCtD
Guanfacine—Immune system disorder—Epirubicin—liver cancer	0.00154	0.00309	CcSEcCtD
Guanfacine—Visual impairment—Doxorubicin—liver cancer	0.00152	0.00305	CcSEcCtD
Guanfacine—Alopecia—Epirubicin—liver cancer	0.00151	0.00303	CcSEcCtD
Guanfacine—Eye disorder—Doxorubicin—liver cancer	0.00147	0.00296	CcSEcCtD
Guanfacine—Tinnitus—Doxorubicin—liver cancer	0.00147	0.00296	CcSEcCtD
Guanfacine—Tension—Epirubicin—liver cancer	0.00146	0.00293	CcSEcCtD
Guanfacine—Dysgeusia—Epirubicin—liver cancer	0.00145	0.00292	CcSEcCtD
Guanfacine—Nervousness—Epirubicin—liver cancer	0.00144	0.0029	CcSEcCtD
Guanfacine—Muscle spasms—Epirubicin—liver cancer	0.00143	0.00287	CcSEcCtD
Guanfacine—Immune system disorder—Doxorubicin—liver cancer	0.00142	0.00286	CcSEcCtD
Guanfacine—Vision blurred—Epirubicin—liver cancer	0.0014	0.00281	CcSEcCtD
Guanfacine—Alopecia—Doxorubicin—liver cancer	0.00139	0.0028	CcSEcCtD
Guanfacine—Ill-defined disorder—Epirubicin—liver cancer	0.00138	0.00277	CcSEcCtD
Guanfacine—Agitation—Epirubicin—liver cancer	0.00136	0.00274	CcSEcCtD
Guanfacine—Tension—Doxorubicin—liver cancer	0.00135	0.00271	CcSEcCtD
Guanfacine—Dysgeusia—Doxorubicin—liver cancer	0.00134	0.0027	CcSEcCtD
Guanfacine—Malaise—Epirubicin—liver cancer	0.00134	0.00269	CcSEcCtD
Guanfacine—Nervousness—Doxorubicin—liver cancer	0.00133	0.00268	CcSEcCtD
Guanfacine—Vertigo—Epirubicin—liver cancer	0.00133	0.00268	CcSEcCtD
Guanfacine—Syncope—Epirubicin—liver cancer	0.00133	0.00267	CcSEcCtD
Guanfacine—Muscle spasms—Doxorubicin—liver cancer	0.00132	0.00265	CcSEcCtD
Guanfacine—Palpitations—Epirubicin—liver cancer	0.00131	0.00264	CcSEcCtD
Guanfacine—Loss of consciousness—Epirubicin—liver cancer	0.0013	0.00262	CcSEcCtD
Guanfacine—Vision blurred—Doxorubicin—liver cancer	0.00129	0.0026	CcSEcCtD
Guanfacine—Convulsion—Epirubicin—liver cancer	0.00129	0.00258	CcSEcCtD
Guanfacine—Hypertension—Epirubicin—liver cancer	0.00128	0.00257	CcSEcCtD
Guanfacine—Ill-defined disorder—Doxorubicin—liver cancer	0.00127	0.00256	CcSEcCtD
Guanfacine—Arthralgia—Epirubicin—liver cancer	0.00126	0.00254	CcSEcCtD
Guanfacine—Chest pain—Epirubicin—liver cancer	0.00126	0.00254	CcSEcCtD
Guanfacine—Myalgia—Epirubicin—liver cancer	0.00126	0.00254	CcSEcCtD
Guanfacine—Agitation—Doxorubicin—liver cancer	0.00126	0.00254	CcSEcCtD
Guanfacine—Anxiety—Epirubicin—liver cancer	0.00126	0.00253	CcSEcCtD
Guanfacine—Discomfort—Epirubicin—liver cancer	0.00125	0.00251	CcSEcCtD
Guanfacine—Malaise—Doxorubicin—liver cancer	0.00124	0.00249	CcSEcCtD
Guanfacine—Dry mouth—Epirubicin—liver cancer	0.00124	0.00248	CcSEcCtD
Guanfacine—Vertigo—Doxorubicin—liver cancer	0.00123	0.00248	CcSEcCtD
Guanfacine—Syncope—Doxorubicin—liver cancer	0.00123	0.00247	CcSEcCtD
Guanfacine—Confusional state—Epirubicin—liver cancer	0.00122	0.00245	CcSEcCtD
Guanfacine—Palpitations—Doxorubicin—liver cancer	0.00121	0.00244	CcSEcCtD
Guanfacine—Oedema—Epirubicin—liver cancer	0.00121	0.00243	CcSEcCtD
Guanfacine—Loss of consciousness—Doxorubicin—liver cancer	0.00121	0.00242	CcSEcCtD
Guanfacine—Shock—Epirubicin—liver cancer	0.00119	0.00239	CcSEcCtD
Guanfacine—Convulsion—Doxorubicin—liver cancer	0.00119	0.00239	CcSEcCtD
Guanfacine—Hypertension—Doxorubicin—liver cancer	0.00119	0.00238	CcSEcCtD
Guanfacine—Tachycardia—Epirubicin—liver cancer	0.00118	0.00238	CcSEcCtD
Guanfacine—Hyperhidrosis—Epirubicin—liver cancer	0.00117	0.00235	CcSEcCtD
Guanfacine—Arthralgia—Doxorubicin—liver cancer	0.00117	0.00235	CcSEcCtD
Guanfacine—Chest pain—Doxorubicin—liver cancer	0.00117	0.00235	CcSEcCtD
Guanfacine—Myalgia—Doxorubicin—liver cancer	0.00117	0.00235	CcSEcCtD
Guanfacine—Anxiety—Doxorubicin—liver cancer	0.00116	0.00234	CcSEcCtD
Guanfacine—Discomfort—Doxorubicin—liver cancer	0.00115	0.00232	CcSEcCtD
Guanfacine—Dry mouth—Doxorubicin—liver cancer	0.00114	0.0023	CcSEcCtD
Guanfacine—Hypotension—Epirubicin—liver cancer	0.00113	0.00227	CcSEcCtD
Guanfacine—Confusional state—Doxorubicin—liver cancer	0.00113	0.00227	CcSEcCtD
Guanfacine—Oedema—Doxorubicin—liver cancer	0.00112	0.00225	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.0011	0.00222	CcSEcCtD
Guanfacine—Shock—Doxorubicin—liver cancer	0.0011	0.00222	CcSEcCtD
Guanfacine—Insomnia—Epirubicin—liver cancer	0.00109	0.0022	CcSEcCtD
Guanfacine—Tachycardia—Doxorubicin—liver cancer	0.00109	0.0022	CcSEcCtD
Guanfacine—Paraesthesia—Epirubicin—liver cancer	0.00109	0.00219	CcSEcCtD
Guanfacine—Hyperhidrosis—Doxorubicin—liver cancer	0.00108	0.00218	CcSEcCtD
Guanfacine—Dyspnoea—Epirubicin—liver cancer	0.00108	0.00217	CcSEcCtD
Guanfacine—Somnolence—Epirubicin—liver cancer	0.00108	0.00216	CcSEcCtD
Guanfacine—Dyspepsia—Epirubicin—liver cancer	0.00107	0.00214	CcSEcCtD
Guanfacine—Decreased appetite—Epirubicin—liver cancer	0.00105	0.00212	CcSEcCtD
Guanfacine—Hypotension—Doxorubicin—liver cancer	0.00105	0.0021	CcSEcCtD
Guanfacine—Fatigue—Epirubicin—liver cancer	0.00104	0.0021	CcSEcCtD
Guanfacine—Constipation—Epirubicin—liver cancer	0.00104	0.00208	CcSEcCtD
Guanfacine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00102	0.00205	CcSEcCtD
Guanfacine—Insomnia—Doxorubicin—liver cancer	0.00101	0.00204	CcSEcCtD
Guanfacine—Paraesthesia—Doxorubicin—liver cancer	0.00101	0.00202	CcSEcCtD
Guanfacine—Dyspnoea—Doxorubicin—liver cancer	0.000999	0.00201	CcSEcCtD
Guanfacine—Feeling abnormal—Epirubicin—liver cancer	0.000998	0.00201	CcSEcCtD
Guanfacine—Somnolence—Doxorubicin—liver cancer	0.000996	0.002	CcSEcCtD
Guanfacine—Gastrointestinal pain—Epirubicin—liver cancer	0.00099	0.00199	CcSEcCtD
Guanfacine—Dyspepsia—Doxorubicin—liver cancer	0.000986	0.00198	CcSEcCtD
Guanfacine—Decreased appetite—Doxorubicin—liver cancer	0.000974	0.00196	CcSEcCtD
Guanfacine—Fatigue—Doxorubicin—liver cancer	0.000966	0.00194	CcSEcCtD
Guanfacine—Constipation—Doxorubicin—liver cancer	0.000958	0.00193	CcSEcCtD
Guanfacine—Abdominal pain—Epirubicin—liver cancer	0.000957	0.00192	CcSEcCtD
Guanfacine—Feeling abnormal—Doxorubicin—liver cancer	0.000923	0.00186	CcSEcCtD
Guanfacine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000916	0.00184	CcSEcCtD
Guanfacine—Hypersensitivity—Epirubicin—liver cancer	0.000892	0.00179	CcSEcCtD
Guanfacine—Abdominal pain—Doxorubicin—liver cancer	0.000886	0.00178	CcSEcCtD
Guanfacine—Asthenia—Epirubicin—liver cancer	0.000869	0.00175	CcSEcCtD
Guanfacine—Pruritus—Epirubicin—liver cancer	0.000857	0.00172	CcSEcCtD
Guanfacine—Diarrhoea—Epirubicin—liver cancer	0.000828	0.00167	CcSEcCtD
Guanfacine—Hypersensitivity—Doxorubicin—liver cancer	0.000825	0.00166	CcSEcCtD
Guanfacine—Asthenia—Doxorubicin—liver cancer	0.000804	0.00162	CcSEcCtD
Guanfacine—Dizziness—Epirubicin—liver cancer	0.000801	0.00161	CcSEcCtD
Guanfacine—Pruritus—Doxorubicin—liver cancer	0.000793	0.00159	CcSEcCtD
Guanfacine—Vomiting—Epirubicin—liver cancer	0.00077	0.00155	CcSEcCtD
Guanfacine—Diarrhoea—Doxorubicin—liver cancer	0.000766	0.00154	CcSEcCtD
Guanfacine—Rash—Epirubicin—liver cancer	0.000763	0.00153	CcSEcCtD
Guanfacine—Dermatitis—Epirubicin—liver cancer	0.000763	0.00153	CcSEcCtD
Guanfacine—Headache—Epirubicin—liver cancer	0.000758	0.00152	CcSEcCtD
Guanfacine—Dizziness—Doxorubicin—liver cancer	0.000741	0.00149	CcSEcCtD
Guanfacine—Nausea—Epirubicin—liver cancer	0.000719	0.00145	CcSEcCtD
Guanfacine—Vomiting—Doxorubicin—liver cancer	0.000712	0.00143	CcSEcCtD
Guanfacine—Rash—Doxorubicin—liver cancer	0.000706	0.00142	CcSEcCtD
Guanfacine—Dermatitis—Doxorubicin—liver cancer	0.000706	0.00142	CcSEcCtD
Guanfacine—Headache—Doxorubicin—liver cancer	0.000702	0.00141	CcSEcCtD
Guanfacine—Nausea—Doxorubicin—liver cancer	0.000665	0.00134	CcSEcCtD
Guanfacine—CYP2C9—Metabolism—GSTA3—liver cancer	8.96e-05	0.00048	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PIK3CG—liver cancer	8.89e-05	0.000476	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.79e-05	0.000471	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTA2—liver cancer	8.76e-05	0.000469	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTA1—liver cancer	8.45e-05	0.000453	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—F2—liver cancer	8.43e-05	0.000452	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—VEGFA—liver cancer	8.41e-05	0.000451	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PSMA4—liver cancer	8.4e-05	0.00045	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PSMD10—liver cancer	8.4e-05	0.00045	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—RAF1—liver cancer	8.37e-05	0.000449	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—NAT2—liver cancer	8.36e-05	0.000448	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTA4—liver cancer	8.2e-05	0.000439	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GOT2—liver cancer	8.18e-05	0.000438	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PIK3CB—liver cancer	8.17e-05	0.000438	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—CSF2—liver cancer	8.15e-05	0.000437	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PIK3CG—liver cancer	8.07e-05	0.000432	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.04e-05	0.000431	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ALDOB—liver cancer	8.01e-05	0.000429	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	8.01e-05	0.000429	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTA2—liver cancer	7.99e-05	0.000428	CbGpPWpGaD
Guanfacine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—liver cancer	7.9e-05	0.000423	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PIK3CD—liver cancer	7.81e-05	0.000419	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TGFB1—liver cancer	7.72e-05	0.000414	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTA1—liver cancer	7.71e-05	0.000413	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYP2E1—liver cancer	7.69e-05	0.000412	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CRABP1—liver cancer	7.64e-05	0.00041	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—NAT2—liver cancer	7.62e-05	0.000408	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—IL2—liver cancer	7.51e-05	0.000402	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ADAM17—liver cancer	7.47e-05	0.000401	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	7.33e-05	0.000393	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ALDOB—liver cancer	7.3e-05	0.000391	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYCS—liver cancer	7.19e-05	0.000385	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PRKCE—liver cancer	7.18e-05	0.000385	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—KRAS—liver cancer	7.15e-05	0.000383	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PIK3CD—liver cancer	7.09e-05	0.00038	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GOT1—liver cancer	7.06e-05	0.000378	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GGT1—liver cancer	7.06e-05	0.000378	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—F2—liver cancer	7.05e-05	0.000378	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PSMA4—liver cancer	7.03e-05	0.000377	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PSMD10—liver cancer	7.03e-05	0.000377	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CRABP1—liver cancer	6.97e-05	0.000373	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.88e-05	0.000369	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PIK3CB—liver cancer	6.81e-05	0.000365	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IGF2—liver cancer	6.8e-05	0.000364	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CG—liver cancer	6.74e-05	0.000361	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—HPGDS—liver cancer	6.68e-05	0.000358	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.64e-05	0.000356	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—PIK3CA—liver cancer	6.57e-05	0.000352	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—F2—liver cancer	6.4e-05	0.000343	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—VEGFA—liver cancer	6.38e-05	0.000342	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—TP53—liver cancer	6.35e-05	0.000341	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CSF2—liver cancer	6.35e-05	0.00034	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTP1—liver cancer	6.34e-05	0.00034	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—RAF1—liver cancer	6.33e-05	0.000339	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	6.27e-05	0.000336	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—H2AFX—liver cancer	6.26e-05	0.000335	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—IL2—liver cancer	6.25e-05	0.000335	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—HMOX1—liver cancer	6.25e-05	0.000335	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CPT1B—liver cancer	6.23e-05	0.000334	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GLUL—liver cancer	6.23e-05	0.000334	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PIK3CB—liver cancer	6.18e-05	0.000331	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CG—liver cancer	6.12e-05	0.000328	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—HPGDS—liver cancer	6.09e-05	0.000326	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—HRAS—liver cancer	6.08e-05	0.000326	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	6.06e-05	0.000325	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.05e-05	0.000324	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NR1H4—liver cancer	6.01e-05	0.000322	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.97e-05	0.00032	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PSMA4—liver cancer	5.95e-05	0.000319	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PSMD10—liver cancer	5.95e-05	0.000319	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CD—liver cancer	5.93e-05	0.000318	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTA3—liver cancer	5.91e-05	0.000317	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TGFB1—liver cancer	5.86e-05	0.000314	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—GSTM1—liver cancer	5.83e-05	0.000312	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GOT2—liver cancer	5.79e-05	0.00031	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—IL2—liver cancer	5.68e-05	0.000304	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TERT—liver cancer	5.66e-05	0.000303	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—CYP1A1—liver cancer	5.52e-05	0.000296	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	5.52e-05	0.000296	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYP2E1—liver cancer	5.45e-05	0.000292	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	5.45e-05	0.000292	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PRKCE—liver cancer	5.44e-05	0.000292	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PSMD10—liver cancer	5.43e-05	0.000291	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PSMA4—liver cancer	5.43e-05	0.000291	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—KRAS—liver cancer	5.42e-05	0.000291	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTA4—liver cancer	5.41e-05	0.00029	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CD—liver cancer	5.38e-05	0.000288	CbGpPWpGaD
Guanfacine—ADRA2B—Hemostasis—AKT1—liver cancer	5.37e-05	0.000288	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GOT2—liver cancer	5.28e-05	0.000283	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.27e-05	0.000283	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTA2—liver cancer	5.27e-05	0.000282	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KDR—liver cancer	5.17e-05	0.000277	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CB—liver cancer	5.17e-05	0.000277	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IGF2—liver cancer	5.16e-05	0.000276	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—MTHFR—liver cancer	5.15e-05	0.000276	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAPK14—liver cancer	5.14e-05	0.000275	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYCS—liver cancer	5.1e-05	0.000273	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTA1—liver cancer	5.08e-05	0.000272	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PPARA—liver cancer	5.05e-05	0.000271	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—ESR1—liver cancer	5.04e-05	0.00027	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—NAT2—liver cancer	5.03e-05	0.000269	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GOT1—liver cancer	5e-05	0.000268	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GGT1—liver cancer	5e-05	0.000268	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—PIK3CA—liver cancer	4.98e-05	0.000267	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—F2—liver cancer	4.98e-05	0.000267	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYP2E1—liver cancer	4.97e-05	0.000266	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—TP53—liver cancer	4.82e-05	0.000258	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALDOB—liver cancer	4.82e-05	0.000258	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CSF2—liver cancer	4.82e-05	0.000258	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	4.81e-05	0.000258	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—RAF1—liver cancer	4.81e-05	0.000258	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—APC—liver cancer	4.77e-05	0.000255	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CG—liver cancer	4.77e-05	0.000255	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—H2AFX—liver cancer	4.75e-05	0.000254	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—IL2—liver cancer	4.74e-05	0.000254	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CB—liver cancer	4.69e-05	0.000251	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYCS—liver cancer	4.65e-05	0.000249	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—HRAS—liver cancer	4.61e-05	0.000247	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CRABP1—liver cancer	4.6e-05	0.000246	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GGT1—liver cancer	4.56e-05	0.000244	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GOT1—liver cancer	4.56e-05	0.000244	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTP1—liver cancer	4.49e-05	0.000241	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—BRAF—liver cancer	4.48e-05	0.00024	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—HMOX1—liver cancer	4.43e-05	0.000237	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CG—liver cancer	4.33e-05	0.000232	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL2—liver cancer	4.31e-05	0.000231	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TERT—liver cancer	4.29e-05	0.00023	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CD—liver cancer	4.19e-05	0.000225	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PPARG—liver cancer	4.17e-05	0.000224	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—PIK3CA—liver cancer	4.15e-05	0.000222	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—SERPINE1—liver cancer	4.14e-05	0.000222	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—GSTM1—liver cancer	4.13e-05	0.000221	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—KRAS—liver cancer	4.1e-05	0.00022	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTP1—liver cancer	4.1e-05	0.000219	CbGpPWpGaD
Guanfacine—ADRA2A—Hemostasis—AKT1—liver cancer	4.07e-05	0.000218	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—HMOX1—liver cancer	4.04e-05	0.000216	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—HPGDS—liver cancer	4.02e-05	0.000215	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KDR—liver cancer	3.93e-05	0.00021	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—CYP1A1—liver cancer	3.91e-05	0.00021	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAPK14—liver cancer	3.9e-05	0.000209	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—ESR1—liver cancer	3.83e-05	0.000205	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CD—liver cancer	3.8e-05	0.000204	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—F2—liver cancer	3.78e-05	0.000203	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—PIK3CA—liver cancer	3.77e-05	0.000202	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—GSTM1—liver cancer	3.76e-05	0.000202	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—ALB—liver cancer	3.75e-05	0.000201	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—RAF1—liver cancer	3.74e-05	0.0002	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CB—liver cancer	3.65e-05	0.000196	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MTOR—liver cancer	3.65e-05	0.000196	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—MTHFR—liver cancer	3.65e-05	0.000195	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CG—liver cancer	3.62e-05	0.000194	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—APC—liver cancer	3.62e-05	0.000194	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PSMD10—liver cancer	3.58e-05	0.000192	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PSMA4—liver cancer	3.58e-05	0.000192	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PPARA—liver cancer	3.58e-05	0.000192	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—CYP1A1—liver cancer	3.57e-05	0.000191	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—HRAS—liver cancer	3.49e-05	0.000187	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GOT2—liver cancer	3.48e-05	0.000187	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CDKN1B—liver cancer	3.43e-05	0.000184	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—BRAF—liver cancer	3.4e-05	0.000182	CbGpPWpGaD
Guanfacine—ADRA2B—GPCR downstream signaling—AKT1—liver cancer	3.39e-05	0.000182	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CASP3—liver cancer	3.36e-05	0.00018	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL2—liver cancer	3.35e-05	0.00018	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—IL6—liver cancer	3.34e-05	0.000179	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—MTHFR—liver cancer	3.33e-05	0.000178	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CB—liver cancer	3.31e-05	0.000178	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYP2E1—liver cancer	3.27e-05	0.000175	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CCND1—liver cancer	3.27e-05	0.000175	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—JUN—liver cancer	3.26e-05	0.000175	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PPARA—liver cancer	3.26e-05	0.000175	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CTNNB1—liver cancer	3.24e-05	0.000174	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.21e-05	0.000172	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CD—liver cancer	3.18e-05	0.00017	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MMP9—liver cancer	3.17e-05	0.00017	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—CDKN1A—liver cancer	3.16e-05	0.00017	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—PIK3CA—liver cancer	3.15e-05	0.000169	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—SERPINE1—liver cancer	3.14e-05	0.000169	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—KRAS—liver cancer	3.11e-05	0.000167	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MAPK8—liver cancer	3.09e-05	0.000165	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling by GPCR—AKT1—liver cancer	3.08e-05	0.000165	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CG—liver cancer	3.06e-05	0.000164	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYCS—liver cancer	3.06e-05	0.000164	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GGT1—liver cancer	3.01e-05	0.000161	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GOT1—liver cancer	3.01e-05	0.000161	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PPARG—liver cancer	2.96e-05	0.000158	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	2.93e-05	0.000157	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—PIK3CA—liver cancer	2.86e-05	0.000153	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—VEGFA—liver cancer	2.85e-05	0.000153	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—RAF1—liver cancer	2.84e-05	0.000152	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—STAT3—liver cancer	2.82e-05	0.000151	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CG—liver cancer	2.79e-05	0.00015	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CB—liver cancer	2.77e-05	0.000149	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MTOR—liver cancer	2.77e-05	0.000149	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTP1—liver cancer	2.7e-05	0.000145	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PPARG—liver cancer	2.7e-05	0.000145	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CD—liver cancer	2.69e-05	0.000144	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—HMOX1—liver cancer	2.66e-05	0.000143	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—ALB—liver cancer	2.66e-05	0.000143	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—HRAS—liver cancer	2.65e-05	0.000142	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—MYC—liver cancer	2.62e-05	0.000141	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TGFB1—liver cancer	2.62e-05	0.00014	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN1B—liver cancer	2.6e-05	0.000139	CbGpPWpGaD
Guanfacine—ADRA2A—GPCR downstream signaling—AKT1—liver cancer	2.57e-05	0.000138	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CASP3—liver cancer	2.55e-05	0.000137	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL2—liver cancer	2.55e-05	0.000136	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—IL6—liver cancer	2.53e-05	0.000136	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—GSTM1—liver cancer	2.48e-05	0.000133	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CCND1—liver cancer	2.48e-05	0.000133	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—JUN—liver cancer	2.48e-05	0.000133	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CTNNB1—liver cancer	2.46e-05	0.000132	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CD—liver cancer	2.46e-05	0.000132	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—ALB—liver cancer	2.42e-05	0.00013	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—KRAS—liver cancer	2.42e-05	0.00013	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MMP9—liver cancer	2.41e-05	0.000129	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—CDKN1A—liver cancer	2.4e-05	0.000129	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—CYP1A1—liver cancer	2.35e-05	0.000126	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CB—liver cancer	2.35e-05	0.000126	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MAPK8—liver cancer	2.34e-05	0.000126	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling by GPCR—AKT1—liver cancer	2.34e-05	0.000125	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—PIK3CA—liver cancer	2.23e-05	0.000119	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—MTHFR—liver cancer	2.19e-05	0.000118	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—VEGFA—liver cancer	2.16e-05	0.000116	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—TP53—liver cancer	2.15e-05	0.000115	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PPARA—liver cancer	2.15e-05	0.000115	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—STAT3—liver cancer	2.14e-05	0.000115	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CB—liver cancer	2.14e-05	0.000115	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—HRAS—liver cancer	2.06e-05	0.00011	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—PIK3CA—liver cancer	2.02e-05	0.000108	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—MYC—liver cancer	1.99e-05	0.000107	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TGFB1—liver cancer	1.99e-05	0.000106	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—IL6—liver cancer	1.97e-05	0.000106	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CG—liver cancer	1.84e-05	9.88e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—KRAS—liver cancer	1.84e-05	9.85e-05	CbGpPWpGaD
Guanfacine—ADRA2B—Signaling Pathways—AKT1—liver cancer	1.82e-05	9.75e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PPARG—liver cancer	1.78e-05	9.53e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—PIK3CA—liver cancer	1.69e-05	9.05e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Metabolism—AKT1—liver cancer	1.65e-05	8.85e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—TP53—liver cancer	1.63e-05	8.76e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CD—liver cancer	1.62e-05	8.68e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—ALB—liver cancer	1.6e-05	8.57e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—HRAS—liver cancer	1.56e-05	8.38e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—IL6—liver cancer	1.5e-05	8.02e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—PIK3CA—liver cancer	1.43e-05	7.67e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CB—liver cancer	1.41e-05	7.57e-05	CbGpPWpGaD
Guanfacine—ADRA2A—Signaling Pathways—AKT1—liver cancer	1.38e-05	7.4e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—PIK3CA—liver cancer	1.31e-05	6.99e-05	CbGpPWpGaD
Guanfacine—CYP2C19—Metabolism—AKT1—liver cancer	1.17e-05	6.27e-05	CbGpPWpGaD
Guanfacine—CYP2C9—Metabolism—AKT1—liver cancer	1.07e-05	5.71e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—PIK3CA—liver cancer	8.61e-06	4.61e-05	CbGpPWpGaD
Guanfacine—CYP3A4—Metabolism—AKT1—liver cancer	7.03e-06	3.77e-05	CbGpPWpGaD
